{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:18:44Z","timestamp":1775024324386,"version":"3.50.1"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T00:00:00Z","timestamp":1453161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0147048","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T15:23:11Z","timestamp":1453216991000},"page":"e0147048","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses"],"prefix":"10.1371","volume":"11","author":[{"given":"Mao","family":"Shu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Zai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,1,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"A Arora","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e102110","DOI":"10.1371\/journal.pone.0102110","article-title":"Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3)","volume":"9","author":"K Yamamoto","year":"2014","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"B Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"RJ Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"SM Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318860-000000000-00000","article-title":"Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies","volume":"23","author":"GS Papaetis","year":"2009","journal-title":"BioDrugs"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors\u2014a review on pharmacology, metabolism and side effects","volume":"10","author":"JT Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy","volume":"6","author":"F Torino","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00345-010-0627-2","article-title":"Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib","volume":"29","author":"LM Riesenbeck","year":"2011","journal-title":"World J Urol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"725410","DOI":"10.1155\/2013\/725410","article-title":"Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment","volume":"2013","author":"H Ahmadieh","year":"2013","journal-title":"Biomed Res Int"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"M Schmidinger","year":"2011","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e1002016","DOI":"10.1371\/journal.pcbi.1002016","article-title":"Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome\u2014clozapine-induced agranulocytosis as a case study","volume":"7","author":"L Yang","year":"2011","journal-title":"Plos Computational Biology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1345\/aph.1A289","article-title":"FDA adverse event reports on statin-associated rhabdomyolysis","volume":"36","author":"MA Omar","year":"2002","journal-title":"Ann Pharmacother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2337\/dc10-2412","article-title":"Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting","volume":"34","author":"C Piccinni","year":"2011","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"W492","DOI":"10.1093\/nar\/gkr299","article-title":"DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome","volume":"39","author":"H Luo","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/bdi.12150","article-title":"Gender differences in thyroid system function: relevance to bipolar disorder and its treatment","volume":"16","author":"M Bauer","year":"2014","journal-title":"Bipolar Disord"},{"key":"ref17","first-page":"101","article-title":"Thyroid disease in the elderly: sex-related differences in clinical expression","volume":"28","author":"S Morganti","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e13946","DOI":"10.5812\/ijem.13946","article-title":"Gender differences in risk factors of congenital hypothyroidism: an interaction hypothesis examination","volume":"12","author":"S Rezaeian","year":"2014","journal-title":"Int J Endocrinol Metab"},{"issue":"Suppl 2","key":"ref19","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1542\/peds.2009-1975F","article-title":"The impact of transient hypothyroidism on the increasing rate of congenital hypothyroidism in the United States","volume":"125","author":"JS Parks","year":"2010","journal-title":"Pediatrics"},{"key":"ref20","first-page":"60","article-title":"Prevalence of cognitive dysfunction and hypothyroidism in an elderly community population","volume":"32","author":"R Luboshitzky","year":"1996","journal-title":"Isr J Med Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12539-011-0051-8","article-title":"Chemical-protein interactome and its application in off-target identification","volume":"3","author":"L Yang","year":"2011","journal-title":"Interdiscip Sci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e9568","DOI":"10.1371\/journal.pone.0009568","article-title":"Identifying unexpected therapeutic targets via chemical-protein interactome","volume":"5","author":"L Yang","year":"2010","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"D1091","DOI":"10.1093\/nar\/gkt1068","article-title":"DrugBank 4.0: shedding new light on drug metabolism","volume":"42","author":"V Law","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"W406","DOI":"10.1093\/nar\/gkp312","article-title":"SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome","volume":"37","author":"L Yang","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1124\/pr.58.4.3","article-title":"International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors","volume":"58","author":"F Flamant","year":"2006","journal-title":"Pharmacol Rev"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1210\/me.2004-0210","article-title":"Heterodimers of retinoic acid receptors and thyroid hormone receptors display unique combinatorial regulatory properties","volume":"19","author":"S Lee","year":"2005","journal-title":"Mol Endocrinol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/355446a0","article-title":"Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling","volume":"355","author":"SA Kliewer","year":"1992","journal-title":"Nature"},{"key":"ref28","first-page":"1468","article-title":"Heterodimerization among thyroid hormone receptor, retinoic acid receptor, retinoid X receptor, chicken ovalbumin upstream promoter transcription factor, and an endogenous liver protein","volume":"6","author":"TJ Berrodin","year":"1992","journal-title":"Mol Endocrinol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1089\/thy.2012.0205","article-title":"Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association","volume":"22","author":"JR Garber","year":"2012","journal-title":"Thyroid"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1744-313X.2009.00830.x","article-title":"Autoimmune thyroid diseases: genetic susceptibility of thyroid-specific genes and thyroid autoantigens contributions","volume":"36","author":"H Hadj-Kacem","year":"2009","journal-title":"Int J Immunogenet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.beem.2009.08.003","article-title":"Drugs that suppress TSH or cause central hypothyroidism","volume":"23","author":"BR Haugen","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199512213332507","article-title":"Drugs and thyroid function","volume":"333","author":"MI Surks","year":"1995","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2006.0308","article-title":"Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity","volume":"17","author":"E Wong","year":"2007","journal-title":"Thyroid"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"P Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"BI Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"J Desai","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbrc.2014.12.096","article-title":"Systematic drug safety evaluation based on public genomic expression (Connectivity Map) data: myocardial and infectious adverse reactions as application cases","volume":"457","author":"K Wang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"ref38","first-page":"6","article-title":"Drug Label Indexing and Mining for Drug Repurposing","volume":"2013","author":"L Yang","year":"2013","journal-title":"Journal of Fudan University (Natural Science)"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"D Mannavola","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2265.2008.03253.x","article-title":"Thyrotoxicosis during sunitinib treatment for renal cell carcinoma","volume":"69","author":"M Grossmann","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","article-title":"The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies","volume":"69","author":"J Ozao-Choy","year":"2009","journal-title":"Cancer Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/thy.2008.0367","article-title":"Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?","volume":"19","author":"F Torino","year":"2009","journal-title":"Thyroid"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1210\/jc.2007-1499","article-title":"Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism","volume":"92","author":"MI Surks","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/thy.2008.0002","article-title":"Factors related to clinical hypothyroid severity in thyroid cancer patients after thyroid hormone withdrawal","volume":"19","author":"SC Huang","year":"2009","journal-title":"Thyroid"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2011.03.002","article-title":"Radiation-induced hypothyroidism in head and neck cancer patients: a systematic review","volume":"99","author":"MJ Boomsma","year":"2011","journal-title":"Radiother Oncol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e1003315","DOI":"10.1371\/journal.pcbi.1003315","article-title":"Prediction of drug-target interactions for drug repositioning only based on genomic expression similarity","volume":"9","author":"K Wang","year":"2013","journal-title":"Plos Computational Biology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12864-015-1516-2","article-title":"Integrated microRNA, mRNA, and protein expression profiling reveals microRNA regulatory networks in rat kidney treated with a carcinogenic dose of aristolochic acid","volume":"16","author":"Z Li","year":"2015","journal-title":"BMC Genomics"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e60598","DOI":"10.1371\/journal.pone.0060598","article-title":"Metabolomic analysis reveals metabolic disturbance in the cortex and hippocampus of subchronic MK-801 treated rats","volume":"8","author":"L Sun","year":"2013","journal-title":"PLoS One"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3892\/mmr.2014.2585","article-title":"Protein-protein interaction analysis of distinct molecular pathways in two subtypes of colorectal carcinoma","volume":"10","author":"H Chen","year":"2014","journal-title":"Mol Med Rep"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"456747","DOI":"10.1155\/2013\/456747","article-title":"An Integrative Platform of TCM Network Pharmacology and Its Application on a Herbal Formula, Qing-Luo-Yin","volume":"2013","author":"B Zhang","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"e1004247","DOI":"10.1371\/journal.pcbi.1004247","article-title":"Modulation of the disordered conformational ensembles of the p53 transactivation domain by cancer-associated mutations","volume":"11","author":"D Ganguly","year":"2015","journal-title":"Plos Computational Biology"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"17031","DOI":"10.18632\/oncotarget.4400","article-title":"A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications","volume":"6","author":"Z Weng","year":"2015","journal-title":"Oncotarget"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jjco\/hys076","article-title":"Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma","volume":"42","author":"M Daimon","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s10637-011-9637-1","article-title":"Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients","volume":"30","author":"Y Fujiwara","year":"2012","journal-title":"Invest New Drugs"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0147048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T16:45:21Z","timestamp":1567529121000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0147048"}},"subtitle":[],"editor":[{"given":"Daniele","family":"Santini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,1,19]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0147048","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,19]]}}}